R

Repligen Corp
D

RGEN

166.730
USD
-1.17
(-0.70%)
مغلق
حجم التداول
27,138
الربح لكل سهم
2
العائد الربحي
-
P/E
-5,558
حجم السوق
9,341,335,859
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALLO
    0.08000
    (4.34%)
    1.92500 USD
    A
    ARCT
    0.260
    (1.58%)
    16.680 USD
    A
    ARWR
    -0.050
    (-0.25%)
    19.710 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    E
    EDIT
    0.15000
    (12.50%)
    1.35000 USD
    F
    FATE
    0.03000
    (2.28%)
    1.34500 USD
    S
    SGMO
    0.03500
    (3.13%)
    1.15500 USD
    V
    VCYT
    -0.550
    (-1.26%)
    43.090 USD
    المزيد
الأخبار
المقالات

العنوان: Repligen Corp

القطاع: Healthcare
الصناعة: Medical Instruments & Supplies
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.